President Trump speaks during a press briefing with FDA commissioner Stephen Hahn (left) and White House coronavirus response coordinator Deborah Birx (right) of the coronavirus task force, at the White House, Thursday, March 19, 2020, in Washington. (AP Photo/Evan Vucci)

March 20, 2020 07:31 AM EDTUpdated 08:30 AM

Coronavirus

Opinion

No, Mr. President, you can’t just order up outbreak meds with the snap of your fingers

Donald Trump was in classic freestyle speaking mode on Thursday as he talked up the immediate production of drugs that can fight the new coronavirus …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

No, Mr. President, you can’t just order up outbreak meds with the snap of your fingers

This article is available only to Premium subscribers

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

No, Mr. Pres­i­dent, you can’t just or­der up out­break meds with the snap of your fin­gers

This article is available only to Premium subscribers

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

No, Mr. President, you can’t just order up outbreak meds with the snap of your fingers

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?